Advances in the development of tau PET radiotracers and their clinical applications

Ageing Research Reviews

Volumn 30, Issue , 2016, Pages 107-113

  Okamura, Nobuyuki ^a,b   Harada, Ryuichi ^b   Furukawa, Katsutoshi ^b   Furumoto, Shozo ^b   Tago, Tetsuro ^b   Yanai, Kazuhiko ^a,b   Arai, Hiroyuki ^b   Kudo, Yukitsuka ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Neurofibrillary tangles; Neuroimaging; Positron emission tomography; Tau proteins

Indexed keywords

CARBON 11; FLUORINE 18; TAU PROTEIN; TRACER; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; COGNITIVE DEFECT; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME; ANIMAL; DIAGNOSTIC IMAGING; PROCEDURES; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TAU PROTEINS; TAUOPATHIES;

EID: 84962052516     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2015.12.010     Document Type: Review

References (58)

1. Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G.M., Small, G.W., Huang, S.C., Barrio, J.R., Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci., 21, 2001, RC189.
2. Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C.M., Lee, V.M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 38 (1995), 649–652.
3. Arnold, S.E., Hyman, B.T., Flory, J., Damasio, A.R., Van Hoesen, G.W., The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1 (1991), 103–116.
4. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992), 631–639.
5. Berg, L., McKeel, D.W. Jr., Miller, J.P., Baty, J., Morris, J.C., Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 50 (1993), 349–358.
6. Bierer, L.M., Hof, P.R., Purohit, D.P., Carlin, L., Schmeidler, J., Davis, K.L., Perl, D.P., Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52 (1995), 81–88.
7. Bobinski, M., Wegiel, J., Wisniewski, H.M., Tarnawski, M., Reisberg, B., De Leon, M.J., Miller, D.C., Neurofibrillary pathology–correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol. Aging 17 (1996), 909–919.
8. Bondareff, W., Mountjoy, C.Q., Roth, M., Hauser, D.L., Neurofibrillary degeneration and neuronal loss in Alzheimer's disease. Neurobiol. Aging 10 (1989), 709–715.
9. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991), 239–259.
10. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., Hof, P.R., Tau protein isoforms: phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000), 95–130.
11. Chetelat, G., La Joie, R., Villain, N., Perrotin, A., de La Sayette, V., Eustache, F., Vandenberghe, R., Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage Clin. 2 (2013), 356–365.
12. Chien, D.T., Bahri, S., Szardenings, A.K., Walsh, J.C., Mu, F., Su, M.Y., Shankle, W.R., Elizarov, A., Kolb, H.C., Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34 (2013), 457–468.
13. Chien, D.T., Szardenings, A.K., Bahri, S., Walsh, J.C., Mu, F.R., Xia, C.F., Shankle, W.R., Lerner, A.J., Su, M.Y., Elizarova, A., Kolb, H.C., Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alzheimers Dis. 38 (2014), 171–184.
14. DeKosky, S.T., Blennow, K., Ikonomovic, M.D., Gandy, S., Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat. Rev. Neurol. 9 (2013), 192–200.
15. Delacourte, A., David, J.P., Sergeant, N., Buee, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., Petit, H., Di Menza, C., The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 (1999), 1158–1165.
16. Devous, M., Joshi, A., Navitsky, M., Kennedy, I., Pontecorvo, M., Mintun, M., Identifying the topology of 18F-AV-1451 (also known as T807) PET tau images for diagnosis and prognosis in neurodegenerative disorders. J. Nucl. Med., 56, 2015, 139.
17. Dickson, D.W., Kouri, N., Murray, M.E., Josephs, K.A., Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45 (2011), 384–389.
18. Fawaz, M.V., Brooks, A.F., Rodnick, M.E., Carpenter, G.M., Shao, X., Desmond, T.J., Sherman, P., Quesada, C.A., Hockley, B.G., Kilbourn, M.R., Albin, R.L., Frey, K.A., Scott, P.J., High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem. Neurosci. 5 (2014), 718–730.
19. Fodero-Tavoletti, M.T., Furumoto, S., Taylor, L., McLean, C.A., Mulligan, R.S., Birchall, I., Harada, R., Masters, C.L., Yanai, K., Kudo, Y., Rowe, C.C., Okamura, N., Villemagne, V.L., Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies. Alzheimers Res. Ther., 6, 2014, 11.
20. Gerson, J.E., Castillo-Carranza, D.L., Kayed, R., Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. ACS Chem. Neurosci. 5 (2014), 752–769.
21. Giacobini, E., Gold, G., Alzheimer disease therapy—moving from amyloid-beta to tau. Nat. Rev. Neurol. 9 (2013), 677–686.
22. Harada, R., Okamura, N., Furumoto, S., Yoshikawa, T., Arai, H., Yanai, K., Kudo, Y., Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain. Mol. Imaging Biol. 16 (2014), 19–27.
23. Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 42 (2015), 1052–1061.
24. Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer's disease. J. Nucl. Med., 2015 (in press).
25. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
26. Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., Yamasaki, T., Yui, J., Xie, L., Ono, M., Hatori, A., Nemoto, K., Suhara, T., Higuchi, M., Zhang, M.R., Radiosynthesis, photoisomerization biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J. Nucl. Med. 55 (2014), 1532–1538.
27. Hashimoto, H., Kawamura, K., Takei, M., Igarashi, N., Fujishiro, T., Shiomi, S., Watanabe, R., Muto, M., Furutsuka, K., Ito, T., Yamasaki, T., Yui, J., Nemoto, K., Kimura, Y., Higuchi, M., Zhang, M.R., Identification of a major radiometabolite of [(11)C]PBB3. Nucl. Med. Biol. 42 (2015), 905–910.
28. Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Kudo, Y., Arai, H., Longitudinal assessment of tau pathology in patients with Alzheimer's disease using [18F]THK-5117 positron emission tomography. PLoS One, 10, 2015, e0140311.
29. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9 (2010), 119–128.
30. Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., Marshall, G., Albers, M., Mauro, S., Pepin, L., Alverio, J., Judge, K., Philiossaint, M., Shoup, T., Yokell, D., Dickerson, B., Gomez-Isla, T., Hyman, B., Vasdev, N., Sperling, R., Tau PET imaging in aging and early Alzheimer's disease. Ann. Neurol., 2015 (in press).
31. Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., Zhang, M.R., Sahara, N., Suhara, T., Higuchi, M., PET quantification of tau pathology in human brain with 11C-PBB3. J. Nucl. Med. 56 (2015), 1359–1365.
32. Lee, V.M., Goedert, M., Trojanowski, J.Q., Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24 (2001), 1121–1159.
33. Li, Y., Tsui, W., Rusinek, H., Butler, T., Mosconi, L., Pirraglia, E., Mozley, D., Vallabhajosula, S., Harada, R., Furumoto, S., Furukawa, K., Arai, H., Kudo, Y., Okamura, N., de Leon, M.J., Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J. Nucl. Med. 56 (2015), 270–273.
34. Marquie, M., Normandin, M.D., Vanderburg, C.R., Costantino, I.M., Bien, E.A., Rycyna, L.G., Klunk, W.E., Mathis, C.A., Ikonomovic, M.D., Debnath, M.L., Vasdev, N., Dickerson, B.C., Gomperts, S.N., Growdon, J.H., Johnson, K.A., Frosch, M.P., Hyman, B.T., Gomez-Isla, T., Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78 (2015), 787–800.
35. Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.R., Trojanowski, J.Q., Lee, V.M., Ono, M., Masamoto, K., Takano, H., Sahara, N., Iwata, N., Okamura, N., Furumoto, S., Kudo, Y., Chang, Q., Saido, T.C., Takashima, A., Lewis, J., Jang, M.K., Aoki, I., Ito, H., Higuchi, M., Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
36. Matsumura, K., Ono, M., Yoshimura, M., Kimura, H., Watanabe, H., Okamoto, Y., Ihara, M., Takahashi, R., Saji, H., Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. Bioorg. Med. Chem. 21 (2013), 3356–3362.
37. Matsumura, K., Ono, M., Kitada, A., Watanabe, H., Yoshimura, M., Iikuni, S., Kimura, H., Okamoto, Y., Ihara, M., Saji, H., Structure-activity relationship study of heterocyclic phenylethenyl and pyridinylethenyl derivatives as tau-imaging agents that selectively detect neurofibrillary tangles in Alzheimer's disease brains. J. Med. Chem. 58 (2015), 7241–7257.
38. Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006), 446–452.
39. Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., Arai, H., Yanai, K., Sawada, T., Kudo, Y., Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25 (2005), 10857–10862.
40. Okamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero-Tavoletti, M., Mulligan, R.S., Villemagne, V.L., Akatsu, H., Yamamoto, T., Arai, H., Iwata, R., Yanai, K., Kudo, Y., Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 54 (2013), 1420–1427.
41. Okamura, N., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Harada, R., Yates, P., Pejoska, S., Kudo, Y., Masters, C.L., Yanai, K., Rowe, C.C., Villemagne, V.L., Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137 (2014), 1762–1771.
42. Okamura, N., Harada, R., Furumoto, S., Arai, H., Yanai, K., Kudo, Y., Tau PET imaging in Alzheimer's disease. Curr. Neurol. Neurosci. Rep., 14, 2014, 500.
43. Ossenkoppele, R., Schonhaut, D.R., Baker, S.L., O'Neil, J.P., Janabi, M., Ghosh, P.M., Santos, M., Miller, Z.A., Bettcher, B.M., Gorno-Tempini, M.L., Miller, B.L., Jagust, W.J., Rabinovici, G.D., Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann. Neurol. 77 (2015), 338–342.
44. Price, J.L., McKeel, D.W. Jr., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Hansen, L.A., Petersen, R.C., Parisi, J.E., Dickson, D.W., Smith, C.D., Davis, D.G., Schmitt, F.A., Markesbery, W.R., Kaye, J., Kurlan, R., Hulette, C., Kurland, B.F., Higdon, R., Kukull, W., Morris, J.C., Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30 (2009), 1026–1036.
45. Rojo, L.E., Alzate-Morales, J., Saavedra, I.N., Davies, P., Maccioni, R.B., Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J. Alzheimers Dis. 19 (2010), 573–589.
46. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L., Villemagne, V.L., Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
47. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N., Szoeke, C., Salvado, O., Head, R., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31 (2010), 1275–1283.
48. Shao, X., Carpenter, G.M., Desmond, T.J., Sherman, P., Quesada, C.A., Fawaz, M., Brooks, A.F., Kilbourn, M.R., Albin, R.L., Frey, K.A., Scott, P.J., Evaluation of [(11)C]N-Methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med. Chem. Lett. 3 (2012), 936–941.
49. Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., Kepe, V., Ercoli, L.M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.C., Barrio, J.R., Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10 (2002), 24–35.
50. Sperling, R., Mormino, E., Johnson, K., The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84 (2014), 608–622.
51. Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., Aisen, P., The A4 study: stopping AD before symptoms begin?. Sci. Transl. Med., 6, 2014, 228fs213.
52. Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K.V., Chetelat, G., Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease. NeuroImage Clin. 2 (2013), 497–511.
53. Villemagne, V.L., Okamura, N., In vivo tau imaging: obstacles and progress. Alzheimers Dement. 10 (2014), S254–264.
54. Villemagne, V.L., Furumoto, S., Fodero-Tavoletti, M.T., Harada, R., Mulligan, R.S., Kudo, Y., Masters, C.L., Yanai, K., Rowe, C.C., Okamura, N., The challenges of tau imaging. Future Neurol. 7 (2012), 409–421.
55. Villemagne, V.L., Fodero-Tavoletti, M.T., Masters, C.L., Rowe, C.C., Tau imaging: early progress and future directions. Lancet Neurol. 14 (2015), 114–124.
56. Whitwell, J.L., Josephs, K.A., Murray, M.E., Kantarci, K., Przybelski, S.A., Weigand, S.D., Vemuri, P., Senjem, M.L., Parisi, J.E., Knopman, D.S., Boeve, B.F., Petersen, R.C., Dickson, D.W., Jack, C.R. Jr., MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71 (2008), 743–749.
57. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 9 (2013), 666–676.
58. Yoshida, M., Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34 (2014), 555–570.